Oncology Melanoma    

FOI REFERENCE: 24409  FOI DATE:  8^th October 2024   

Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

• Cobimetinib   0 patients
• Dabrafenib 0 patients
• Dabrafenib + Trametinib 5 patients
• Dacarbazine 0 patients
• Denosumab 0 patients
• Encorafenib + Binimetinib 0 patients
• Ipilimumab monotherapy 0 patients
• Ipilimumab + Nivolumab 0 patients
• Nivolumab monotherapy 0 patients
• Nivolumab + Relatlimab 0 patients
• Pembrolizumab 12 patients
• Trametinib 0 patients
• Vemurafenib 0 patients
• Vemurafenib + Cobimetinib 0 patients
• Other active systemic anti-cancer therapy Not applicable
• Palliative care only

Q2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

• Ipilimumab monotherapy 0 patients
• Ipilimumab + Nivolumab 0 patients
• Nivolumab monotherapy 0 patients
• Nivolumab + Relatlimab 0 patients
• Pembrolizumab    0 patients
• Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib  /Trametinib  /Vemurafenib  /Vemurafenib AND Cobimetinib)  0 patients
• Other active systemic anti-cancer therapy 0 patients
• Palliative care only 0 patients

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?

• Ipilimumab (monotherapy) 0 patients
• Nivolumab (monotherapy) 0 patients
• Nivolumab AND Ipilimumab (combination) 0 patients
• Nivolumab AND Relatlimab 0 patients
• Pembrolizumab 3 patients
• Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) 0 patients
• Other active systemic anti-cancer therapy   0 patients

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.